Last reviewed · How we verify
Dapagliflozin or Empagliflozin — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Dapagliflozin or Empagliflozin (Dapagliflozin or Empagliflozin) — Yonsei University.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Dapagliflozin or Empagliflozin TARGET | Dapagliflozin or Empagliflozin | Yonsei University | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Dapagliflozin or Empagliflozin CI watch — RSS
- Dapagliflozin or Empagliflozin CI watch — Atom
- Dapagliflozin or Empagliflozin CI watch — JSON
- Dapagliflozin or Empagliflozin alone — RSS
Cite this brief
Drug Landscape (2026). Dapagliflozin or Empagliflozin — Competitive Intelligence Brief. https://druglandscape.com/ci/dapagliflozin-or-empagliflozin. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab